<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00120575</url>
  </required_header>
  <id_info>
    <org_study_id>BMT CVVH</org_study_id>
    <nct_id>NCT00120575</nct_id>
  </id_info>
  <brief_title>Hemofiltration for Respiratory Failure After Bone Marrow Transplantation</brief_title>
  <official_title>Hemofiltration for Respiratory Failure Following Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      For children undergoing bone marrow transplantation, respiratory failure is a devastating
      complication, with mortality expectations well above 60%. The researchers have devised a
      novel strategy that may greatly improve survival. Hemofiltration, a continuous form of
      dialysis, was designed as a therapy for critically ill patients with kidney failure. A
      semi-permeable membrane removes plasma water and solutes (up to about 35,000 Daltons
      molecular weight). The researchers have treated immuno-compromised children with respiratory
      failure with hemofiltration. Many inflammatory molecules are of a size well below the limit
      of the filter. Hemofiltration might remove a critical amount of this inflammatory material,
      attenuating the unregulated inflammatory response that is central to the development of
      respiratory failure and progression to multiple organ failure and death. The researchers are
      conducting a multi-center trial of early continuous hemofiltration for respiratory failure in
      children following bone marrow transplantation. The researchers will analyze blood and
      ultrafiltrate using sensitive proteomic methods to detect several inflammatory biochemicals
      known to be active in this disease, looking for evidence that early active hemofiltration
      alters the inflammatory response. The researchers will test whether `early` hemofiltration
      produces greater survival from respiratory failure in this vulnerable population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For children undergoing bone marrow transplantation, respiratory failure carries mortality
      expectations well above 60%. The researchers have published preliminary evidence that
      continuous hemofiltration may greatly improve survival, if filtration is begun when the child
      first fulfills clinical criteria for ARDS. This is a departure from standard practice, as
      hemofiltration is usually begun later in the course (if at all) when multiple organ failure
      is entrenched. Hemofiltration, a `renal replacement therapy` for critically ill patients, is
      a slow, continuous process in which a semi-permeable membrane removes plasma water and
      solutes (up to about 35 kiloDaltons). Many cytokine and chemokine molecules are smaller than
      the molecular weight limit of the filter; hemofiltration might remove a critical amount,
      attenuating the unregulated inflammatory response responsible for respiratory failure and
      progression to multiple organ failure and death. The researchers will conduct a multi-center
      randomized trial assessing the effect of hemofiltration on survival from respiratory after
      bone marrow (or more precisely, hematopoietic stem cell) transplantation. The researchers
      will perform sensitive proteomic assays of serum and ultrafiltrate, to detect the presence of
      cytokines and chemokines known to be active in idiopathic pneumonia syndrome. Resulting
      profiles will constitute a uniquely complex description of ultrafiltrate and may provide
      evidence for modulation of immune function by hemofiltration.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2005</start_date>
  <completion_date>September 2008</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>PELOD organ failure score</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of ventilator-free days</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of hospitalization</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>functional outcome score</measure>
  </secondary_outcome>
  <enrollment>112</enrollment>
  <condition>Bone Marrow Transplantation</condition>
  <condition>Respiratory Insufficiency</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hemofiltration</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hematopoietic stem cell recipient

          -  respiratory failure fulfilling ARDS criteria

          -  mechanical ventilation (invasive / non-invasive)

        Exclusion Criteria:

          -  extracorporeal membrane oxygenation (ECMO)

          -  predominance of congestive heart failure

          -  code status: a patient must be willing to accept invasive mechanical ventilation if
             clinically indicated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph V DiCarlo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joseph V DiCarlo, MD</last_name>
    <phone>(650) 497-8850</phone>
    <email>jdicarlo@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital and Research Center</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vivienne Newman, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vivienne Newman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta @ Egleston</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Fortenberry, MD</last_name>
    </contact>
    <investigator>
      <last_name>James Fortenberry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ira Cheifetz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ira Cheifetz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vinay Nadkarni, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vinay Nadkarni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Skippen, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Gordon Krahn</last_name>
    </contact_backup>
    <investigator>
      <last_name>Peter Skippen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helmut Hummler, MD</last_name>
    </contact>
    <investigator>
      <last_name>Helmut Hummler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quen Mok, MB BS</last_name>
    </contact>
    <investigator>
      <last_name>Quen Mok, MB BS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>DiCarlo JV, Alexander SR, Agarwal R, Schiffman JD. Continuous veno-venous hemofiltration may improve survival from acute respiratory distress syndrome after bone marrow transplantation or chemotherapy. J Pediatr Hematol Oncol. 2003 Oct;25(10):801-5.</citation>
    <PMID>14528104</PMID>
  </reference>
  <reference>
    <citation>Di Carlo JV, Alexander SR. Hemofiltration for cytokine-driven illnesses: the mediator delivery hypothesis. Int J Artif Organs. 2005 Aug;28(8):777-86. Review.</citation>
    <PMID>16211527</PMID>
  </reference>
  <verification_date>December 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2005</study_first_submitted>
  <study_first_submitted_qc>July 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2005</study_first_posted>
  <last_update_submitted>December 1, 2006</last_update_submitted>
  <last_update_submitted_qc>December 1, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2006</last_update_posted>
  <keyword>Hemofiltration</keyword>
  <keyword>Pediatrics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

